My last post discussed an email recently sent from the Burzynski Clinic to someone who had made an initial enquiry through the clinic’s website.
This post concerns another email from the clinic, sent about a year ago to parents who were looking into treatment for their child’s brain tumour. Although the family have not contacted me directly and wish to remain anonymous, it is my understanding that they are happy for this information to be made public.
The email itself and the attachments are misleading in several ways. For example, it is stated that antineoplastons have few, if any side effects. In fact there is well known and significant toxicity.
It is stated that it is a targeted gene therapy. I do not believe that is the case.
The attached documents give a strong overall impression that antineoplastons are an effective cancer treatment. However, the Burzysnski Clinic have not published sufficient data to substantiate any such claims or implications.
It also strikes me as rather strange that the clinic are suggesting that prospective patients talk to current or former patients when they are deciding whether to go ahead with the treatment.
The email contained seven attached documents:
The text of the email reads
Phase III is not finalized yet, but we may treat the child on an individual permission from the FDA.
So, please send us medical records for an evaluation. Standard info attached.
The ‘Standard info’ was as follows
Dear International Patient,
Thank you for your interest in our clinical trials.
For patients with primary brain tumors, we may be able to offer Antineoplastons, an experimental gene therapy that is in Phase II clinical trials at this time at our clinic. The medication is made up of naturally occurring peptides, amino acid derivatives and certain organic acids that fight cancer with few, if any, side effects. It is a targeted gene therapy that does not harm healthy cells or other body tissues. Not all patients qualify to participate in these clinical trials.
Before the patient starts the treatment, our medical staff must first determine if the patient is a candidate for the treatment, and if so, what modality of treatment should be prescribed. In order for us to
make this decision, the patient needs to provide detailed medical records for the review. It is mandatory that the medical records include
1. pathology/biopsy report(s),
2. summary of the previous treatments (see Patient Screening Form),
3. latest laboratory tests (blood and urinalysis),
4. written reports of latest MRI, PET, CT-scan, or bone scan report –
whichever applies, (no films please unless requested).
These reports must not be older than 60 days, with the exception of the pathology report. Reports should be translated into English.
There is a $500.00 fee for medical history review payable by check,
money order, credit card or wire transfer. This fee is non-refundable,
and it does not guarantee admission to the protocol.
Wire transfer instruction:
S.R. Burzynski, M.D., Ph.D.
Wells Fargo Bank
Acc # 2001144559
ABA (domestic) # 121000248
SWIFT (international) Code: WFBIUS6S
901 Gessner Rd.
Houston, Texas 77024-2501
phone: (800) 869-3557
Please include patient’s name in all transactions.
Patients with brain tumours can be treated only under Dr. Burzynski’s direct care and it will be most likely intravenous treatment. This means that those patients will have to come to the US for 3-4 weeks in order to begin the treatment. Then the treatment which often lasts for a year or even longer may be continued under the care of a local physician.
For children we require a care of pediatric oncologist.
We are an outpatient facility, so patient should be in a condition allowing daily transportation between clinic and hotel or motel. For your convenience I attach accommodation info in a Word document format.
The cost of therapies breaks down as follows:
– Medical History Review: $500
– Consultation fee: $1,000
– Deposit to begin therapy: $18,000 (physician and nursing care while
in Houston, medical supplies & infusion pump)
– Monthly deposits for case management and supplies at home: $7,600
– Catheter insertion: Adults $1,500 / Children Approximately $6000
The cost for the catheter insertion is ONLY if the patient does not have a port a cath in yet (this can be done with doctors at home prior to coming to
the Burzynski Clinic).
The therapy regimen generally lasts up to a year on average for most patients.
Remember these are just estimates. While not inexpensive, this therapy may be less expensive than standard radiation or chemotherapy treatments.
These numbers will range depending on various factors, such as length of therapy or the general condition of the patient at the start of the therapy.
For those who qualify for the antineoplaston therapy, a central venous catheter will be surgically placed in the subclavian vein, right beneath the
collarbone. During the stay in Houston, patients and the caretakers will undergo training on how to administer medications through the pump
and how to care for the catheter site. The pump is portable and will administer the medication at regularly scheduled/programmed intervals.
After consulting with our clinic physicians and talking to former or current patients, prospective patients decide whether or not to initiate therapy.
Once the therapy has begun and the medications and dosages are determined, the clinic’s insurance department can submit the paperwork to the patient’s insurance company for a decision. The patient must be prepared to pay the
expenses up front until a decision is made. However, it is important to note that this therapy may or may not be covered by insurance. In addition,
Medicare and Medicaid WILL NOT pay for the medications or services provided by our clinic.
Please feel free to call me at (713) 335-5601 if you have additional questions. I am available Mon. – Fri. 10:00am to 4:30pm Houston time (US CDT), that’s 17:00 to 23:30 Central Europe Time. My e-mail: firstname.lastname@example.org
There is also independent Patient Group website at:
Adam S. Golunski
Again – before we can say anything, we need to see patient’s medical records. Below is a list of required records. In order to evaluate any patient, we NEED to have the following information:
– Pathology/biopsy report(s), except for brain tumors of dangerous location,
– Last MRI report (for brain tumors)
– Last PET scan report (advised)
– Last CT scan report (if applicable)
– Last bone scan report (if applicable)
– Latest laboratory tests: blood (blood counts & biochemistry) and urinalysis,
– Summary of past treatment (see Patient Screening Form)
The patient has to be off any treatment in order to be accepted forantineoplaston treatment at our clinic. We may accept the patient:
a/ after successfull chemotherapy – 4 weeks after last dose,
b/ after successfull radiation – 8 weeks after last procedure,
c/ immediately, if there is proven progression of the disease during or
right after above mentioned treatments.
In order to be qualified for Clinical Trials with antineoplastons the patient has to have previous radiaton and chemotherapy treatments.
If the patient did not have chemo and radiation we can still treat her/him within Gene Targeted Therapy individual program.
Note that we do not need any films at this time, just written reports.
You can fax them to me at (713) 335-5601.
PATIENT SCREENING FORM
PLEASE RETURN THIS FORM ALONG WITH YOUR RECORDS TO:
S.R. Burzynski, MD, Ph.D.
Adam S. Golunski
9432 Katy Freeway, Suite 200
Houston, TX 77055
Phone/fax: (713) 335-5601
This form has to be fully completed before an evaluation can be made.
SECTION I – PATIENT INFORMATION
State: Postal Code:
Date of birth: SS#:
Patient’s Age: Sex: M F Height: cm
Normal Weight: lb/kg Present Weight: lb/kg
PERSON TO CONTACT (if other than the patient)
SECTION II – ORIGINAL CANCER DIAGNOSIS
Original Cancer Type:
Date of Diagnosis:
Original Site of Diagnosis:
Biopsy Confirmed (Y)es/(N)o: Type/Grade:
Stage: Metastases (spread) Site/s:
Date of Metastatic Diagnosis:
SECTION III – SURGERY
Surgery for Original Diagnosis (Y)es/(N)o:
% of Tumor or Cancer Removed: Size:
Other Details of Surgery:
SECTION IV – CHEMOTHERAPY
Date Treatment Initiated:
Type, Dosage, and Number of Treatments of Each
SECTION V – RADIATION
Date Treatment Initiated:
Radiation Absorbed Dose (Rads):
SECTION VI – OTHER THERAPIES
Other Therapies/Drugs (Past):
Other Therapies/Drugs (Present):
SECTION VII – PRESENT CONDITION
Is Patient Ambulatory? (Y)es/(N)o:
Short of breath (Y)es/(N)o:
Fluid retention (Y)es/(N)o:
In Pain (Y)es/(N)o:
On oxygen (Y)es/(N)o:
KPS (Karnofsky Performance Scale) VERY IMPORTANT !!!
Please CHECK ONLY ONE of the following patient’s
condition description (100 through 20):
100 – Normal, no complaints, no evidence of disease;
90 – Able to carry on normal activity, minor symptoms of
80 – Normal activity with effort, some symptoms of disease;
70 – Cares for self, unable to carry on normal activity or
60 – Requires occasional assistance but is able to care
for own needs;
50 – Requires considerable assistance and frequent medical care;
40 – Disabled, requires special care and assistance;
30 – Severely disabled, hospitalization is indicated, death
is not imminent;
20 – Very sick, hospitalization necessary, active treatment
Patient’s Overall Condition / Attitude:
SECTION VIII – PATIENT’S PHYSICIAN
The FDA REQUIRES patients participating in Clinical Trials
to maintain a relationship with a local Physician who will
assist Dr. Burzynski during the course of the treatment
with follow-up of the patient, as needed, by diagnostic
testing such as lab work, X-Rays, MRI’s, CT Scans, etc.,
and evaluation of the patient’s condition. Please complete
================================================END OF FORM
Blood tests required for evaluation:
1. CBC = complete blood count,
2. CHEM 27:
BUN (blood urea nitrogen)
3. coagulation study